Pharmaceutical

Image

Global Acute Lobar Nephronia Treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Jan 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Acute Lobar Nephronia Treatment Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 8.90 Billion
Diagram Market Size (Forecast Year) USD 11.72 Billion
Diagram CAGR %

Global Acute Lobar Nephronia Treatment Market, By Type (Single Lobe Infection and Multiple Lobe Infection), Drug (Antibiotics, Anti-Inflammatory, Analgesics), Drug Type (Branded and Generics), Route of Administration (Oral and Parenteral), Population Type (Children and Adults), End Users (Hospitals, Specialty Clinics Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.

Acute Lobar Nephronia Treatment Market Analysis and Size

Acute lobar nephronia is normally witnessed in children. This condition is being increasingly diagnosed due to the advancement of imaging technology. The rise in paediatric population, growing cases of bacterial infection, and increased innovations in the disease treatment field will boost the market growth. Around 25% of the children with this condition may progress into renal abscess if not treated with suitable and adequate intravenous antibiotics

Data Bridge Market Research analyses that the acute lobar nephronia treatment market is expected to reach USD 11.72 billion by 2030, which is USD 8.9 billion in 2022, and is expected to undergo a CAGR of 3.50% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Acute Lobar Nephronia Treatment Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Single Lobe Infection and Multiple Lobe Infection), Drug (Antibiotics, Anti-Inflammatory, Analgesics), Drug Type (Branded and Generics), Route of Administration (Oral and Parenteral), Population Type (Children and Adults), End Users (Hospitals, Specialty Clinics Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Hikma Pharmaceuticals PLC (U.K.), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Antares Pharma (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi USA (U.S.), Accord Healthcare, Inc. (U.S.), GSK plc (U.K.), Lilly (U.S.), Abbott (U.S.), Sanofi (France), Bayer AG (Germany), Amgen Inc. (U.S.)

Market Opportunities

  • Increasing Prevalence of Acute lobar nephronia treatment
  • Increased Demands of Diagnostic Tests

Market Definition

Acute lobar nephronia, is also termed as acute focal pyelonephritis or acute focal bacterial pyelonephritis. It is a non-liquefactive focal severe infection involving one or more renal lobules. It is a type of medical renal disease that presents as a febrile urinary tract infection. The typical symptoms include fever, leukocytosis, pyuria, flank pain, and bacteriuria, which are similar to those with renal abscess.

Acute Lobar Nephronia Treatment Market Dynamics

Drivers

  • Extensive Availability of Advanced Treatment Procedures

Patients with this rare disorder demand appropriate antibiotics by intravenous administration for a minimum period of two weeks, followed by one week of oral antibiotics. This condition is generally a slow response to antibiotics and generally, the fever settles only by the end of one week of IV antibiotics and it is essential to have an image follow-up in the second week. Furthermore, surgical intervention is required in the 25% of the cases where the lesion turns to renal abscess. In cases with the slightest doubt of malignancy, open biopsy of the lesion is warranted. The main standard for diagnosis is to get a tissue diagnosis of the lesion. This boosts the market growth.

Opportunities

  • Increased Demands of Diagnostic Tests

Acute lobar nephronia treatment patients emphasize radiographic findings as an important way for further treatment through detailed clinical evaluation, identification of characteristic findings, and numerous advanced imaging techniques. Imaging is essential in deciding on the course of management of the disease. Ultrasonography is the standard diagnosis in identifying the hypoechoic lesion in the kidney with or without areas of liquefaction. Thus, these several diagnostic techniques faster the treatment processes to begin.   

  • Increasing Prevalence of Acute Lobar Nephronia

The increasing incidence of this rare syndrome is creating more opportunity for the market growth. Acute lobar nephronia is related to a high prevalence of renal scarring compared to acute phosphate nephropathy. The incidence of acute lobar nephronia varies from 17% to 42% in children. Thus, the growing occurrence demands more treatment procedures, creating opportunities for its growth.

Restraints/Challenges

  • Unavailability of Appropriate Treatments

To treat conditions that are rare, many a times all treatments are not available, particularly in under-developed countries. The severe patients need to be treated with advanced techniques, but these are sometimes unavailable in the hospitals and clinics. Thus, it impedes the market growth.

This acute lobar nephronia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute lobar nephronia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Acute Lobar Nephronia Treatment Market Scope

The acute lobar nephronia treatment market is segmented on the basis of type, drug, drug type, route of administration, population type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Single Lobe Infection
  • Multiple Lobe Infection

Drug

  • Antibiotics
  •  Anti-Inflammatory
  • Analgesics

Drug Type

  • Branded
  • Generics

Route of Administration

  • Oral
  • Parenteral

Population Type

  • Children
  • Adults

End Users

  • Hospitals
  • Specialty Clinic
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Acute Lobar Nephronia Treatment Market Regional Analysis/Insights

The acute lobar nephronia treatment market is analyzed and market size insights and trends are provided by type, drug, drug type, route of administration, population type, distribution channel and end-user as referenced above.

The major countries covered in the acute lobar nephronia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market in the forecast period because of the strong reimbursement policies in the U.S. and increasing awareness and research towards this disease. 

Asia-Pacific is considered to have the most lucrative period because of the increasing research and development investments and rising expenditure on healthcare.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Acute Lobar Nephronia Treatment Market Share Analysis

The acute lobar nephronia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acute lobar nephronia treatment market

Key players operating in the acute lobar nephronia treatment market include:

  • Hikma Pharmaceuticals PLC (U.K.)
  • Pfizer Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Antares Pharma (U.S.)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Fresenius Kabi USA (U.S.)
  • Accord Healthcare, Inc. (U.S.)
  • GSK plc (U.K.)
  • Lilly (U.S.)
  • Abbott (U.S.)
  • Sanofi (France)
  • Bayer AG (Germany)
  • Amgen Inc. (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The acute lobar nephronia treatment market value was USD 8.9 billion in 2022.
The acute lobar nephronia treatment market is projected to grow at a CAGR of 3.50% during the forecast period of 2023-2030.
The Acute Lobar Nephronia Treatment Market report is segmented by type, drug, population, route of administration, distribution channel & end-user.
North America is dominating the market in the forecast period because of the strong reimbursement policies in the U.S. and increasing awareness and research towards this disease.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials